Elicio Therapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview

Elicio Therapeutics

09/08/2025 01:28

Elicio Therapeutics Inc ELTX.OQ ELTX.O is expected to  show no change in quarterly revenue when it reports  results  for the period ending September 30 2025

​LSEG's mean analyst estimate for Elicio Therapeutics Inc is for a loss of 51 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 3.3% in the last three months. ​

Wall Street's median 12-month price target for Elicio Therapeutics Inc is $12.50, about 26.4% above its last closing price of $9.20

This summary was machine generated August 9 at 00:28 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)